Tracked in our index — here's what we can read so far.
Running 5/30 days across 1 GEO.
Running in a single market (United States) — a focused test, not a broad rollout yet.
- Seen 5/30 days
- 1 GEO
- Redirect chain checked
- LP host: forbes.com
Reverse-engineered from the live ad — longevity, GEOs, and the affiliate funnel behind it. Verified by following the redirect chain on Apr 30. Free, no login.
Funnel, reverse-engineered
The campaign behind this creative
← the actual path the money takes.
Creative
Forbes
Landing page
forbes.com
where it lands
Product / Offer: not detected
Tracker: not detected
Affiliate network: not detected
How we know: the tracker and affiliate network come from the live redirect chain we followed and fingerprinted hop by hop. Greyed nodes weren’t detected.
Went quiet
running 5d · last seen 48d ago · 1 market
No fresh sightings in over a week — momentum has dropped. Study it, don't chase it.
Gravity
—
push pressure now · 30d index
Strength
4/100
overall scale · 30d index
Run
5d
last seen 48d ago
Markets
1
countries seen
Landing page
forbes.com
screenshot on file
Screenshot
Captured
LP rendered
Operator
—
unidentified
Network
Outbrain
traffic source
Not Ozempic! These Are The Best GLP-1 Medications of 2026
Forbes@forbes
Top 25% longevity in network
Days alive is a profitability proxy — advertisers don’t pay to run losers.
Seen in
Geo reach
Single-geo testa single marketPredominantly Tier 1, concentrated in North America — United States.
What the data shows
Forbes's Outbrain creative has been running for 5 days across 1 country and first seen on April 24, 2026 and last seen on April 30, 2026. It has been observed in United States. The ad lands on forbes.com. Forbes is running 8 other creatives we have indexed, linked below for side-by-side comparison.
Creative headline: Not Ozempic! These Are The Best GLP-1 Medications of 2026. Indexed on Outbrain by mediabuyer.
Landing-page intelligence
Landing page intelligence
Where this ad lands · www.forbes.com
The lander is the product — screenshot, redirect chain, offer, tech stack, and on-page text in one place.
Landing page
www.forbes.com
1 page · final host: www.forbes.com
Host
forbes.com
Path
/health/l/best-glp-1-medications-price/
Full URL
Redirect chain
Chain not captured yet.
Final host: forbes.com. Hop-by-hop capture runs as a separate pipeline; ads observed in recent ingests get crawled first.
Tracking parameters
- check
- b
- utm_source
- outbrain
- utm_campaign
- 004c628bb9af56b17f5f6e28f31f683051
- accountid
- 003cd3fca64f3e35c2760c979244e1e556
- utm_content
- [publisher_id]
- utm_term
- [publisher_name]
- network
- outbrain
- placement
- [publisher_id]
- creative
- 00b0af772942675e9e5e4d1e2b7cbaa7fe
- utm_source
- outbrain
- utm_medium
- paid_native
- obclid
- [ob_click_id]
- ecom_creative
- 004c628bb9af56b17f5f6e28f31f683051
Tracking setup · Outbrain
Outbrain emits ob_click_id (your unique click), ob_source (publisher), ob_section (placement), and ob_position. Forward ob_click_id to your tracker as the postback key. ob_source and ob_section are the two highest-signal sub-IDs for blacklisting.
?ob_click_id={ob_click_id}&ob_source={ob_source}&ob_section={ob_section}&ob_position={ob_position}Default Outbrain setup template: ?ob_click_id={ob_click_id}&ob_source={ob_source}&ob_section={ob_section}&ob_position={ob_position}
Tech stack
No third-party monetization stack detected — this appears to be a direct landing page.
Landing page hubs
Landing page text
On-page text not extracted yet.
Observed daily (last 30 days)
No observations in this window.
Auto-summary
At a glance
Outbrain direct LP. Lead-gen / DTC. Running in 🇺🇸 United States. Active 5 days.
Sibling creatives from this campaign
Other creatives in Nutra on Outbrain
The rest of the set they’re running — see what else this angle is paired with.
Tirzepatide Microdosing Crushes Ozempic - Only $79/month
US seniors eligible for walk-in tubs if their house has this (Check eligibility)
Forbes Reveals These GLP-1 Treatments Are #1 For Weight Loss - Only $3/day
Lock in Lowest Tirzepatide Price Ever - Only $79/month
Skip Ozempic! Forbes Reveals Affordable GLP-1 Medications of 2026
Tirzepatide Crushes Ozempic - Lock in Lowest Price Ever $79/month
Avoid Expensive Meal Plans - Try This Instead For Weight Loss
Skip Ozempic! These Are The Best GLP-1 Medications of 2026
Tested headline variants8
Tested headline variants
Forbes's own A/B test — which headline they kept
The advertiser’s own A/B result, handed over: ranked by days running, the survivor on top. Variants they stopped running are struck through — they tested and killed those angles.
- #1Skip Ozempic! These Are The Best GLP-1 Medications of 2026Winning angle59d6 content tokens
- #2Skip Ozempic! Forbes Reveals Affordable GLP-1 Medications of 202629d8 content tokens
- #3Tirzepatide Microdosing Crushes Ozempic - Only $79/month6d7 content tokens
- #4Lock in Lowest Tirzepatide Price Ever - Only $79/month6d8 content tokens
Winning angle: the headline they kept alive longest — it beat the other variants they tested. Model this one; treat the rest as discarded experiments.
More from Forbes8
More from Forbes
Most spy tools stop at the creative. This page connects it to the campaign behind it — the funnel, the longevity, the GEOs. Free.